Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.

Paul G RichardsonSchjesvold FredrikKatja WeiselPhillipe MoreauLarry D AndersonDarrell WhitePaula Rodriguez-OteroPieter SonneveldMonika EngelhardtMatthew JennerAlessandro CorsoJan DürigMichel PavicMorten SalomoMeral BeksacAlbert OrtiolJindriska LindsayAnna Marina LiberatiMonica GalliPawel RobakAlessandra LaroccaMunci YagciFiliz VuralAbraham S KanateRuiyun JiangLara GroteTeresa PelusoMeletios- Athanasios Dimopoulos

Published in: European journal of haematology (2021)

These findings confirmed the benefits of PVd at first relapse, including in patients with poor prognostic factors.

Keyphrases

multiple myeloma
prognostic factors
free survival
newly diagnosed
low dose
high dose